CDKN2AIPNL

Across TCGA pan-cancer cohorts, CDKN2AIPNL mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of CDKN2AIPNL’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where CDKN2AIPNL mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types CDKN2AIPNL is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

CCRCC, LSCC, and HNSC are the cancer types where CDKN2AIPNL tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CDKN2AIPNL mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	All	+0.749	<.001	10	view →
LSCC	Male	II,III,IV	+0.272	<.001	5	view →
HNSC	Male	All	+0.226	<.001	5	view →
PDAC	Female	II,III,IV	−0.361	.012	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

CDKN2AIPNL–CCRCC

Open the CCRCC breakdown →